4.5 Review

Sex differences in psychopathology: Of gonads, adrenals and mental illness

Journal

PHYSIOLOGY & BEHAVIOR
Volume 97, Issue 2, Pages 250-258

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.physbeh.2009.02.033

Keywords

17-beta estradiol; Glucocorticoids; Depression; Corticotrophin releasing hormone; Estrogen receptors; Hypothalamic pituitary-adrenal axis; Serotonin; Forced swim test; Elevated plus maze; Open field; Anxiety

Funding

  1. [MH069725]
  2. [AG12962]

Ask authors/readers for more resources

Stress-related disorders such as anxiety and depression are disproportionately prevalent in women. Women are more likely to experience depression and anxiety disorders during periods of marked hormonal fluctuations, suggesting that gonadal hormones are involved in stress pathology. Depression and anxiety are both associated with aberrant secretion of glucocorticoids, which also show marked fluctuations across the reproductive cycle and in response to gonadal steroids. Thus, interactions between gonadal and stress hormones may play a major role in predisposing females to stress-related disease. The purpose of this brief review is to highlight preclinical data regarding the role of estrogens in depression and anxiety-like behaviors. While it is evident the exogenous estrogens modulate affective behavior in rodents, there is some disagreement in the literature, perhaps related to experimental designs that vary with respect to administration parameters and stress. Beneficial effects of estrogens on mood are most likely due to estrogen receptor (ER)beta signaling. The antidepressant and anxiolytic effects of ER beta are consistent with its role in attenuating glucocorticoid responses to stress, suggesting that estrogens, acting at ER beta, may improve mood by suppressing glucocorticoid hyperactivity. However, additional studies demonstrate that ER beta signaling in the hippocampus is sufficient to induce antidepressant and anxiolytic behaviors. Thus, ER beta may improve mood via primary actions on hypothalamic (i.e., paraventricular nucleus) and/or extrahypothalamic sites. Overall, the preclinical research suggests that selective ER modulators targeting ER beta may be an attractive alternative or adjunct treatment to currently prescribed antidepressants or anxiolytics. (c) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available